Open-label, Phase I, Multi-center Study to Determine in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients the Recommended Dose of CYAD-02 After a Non-myeloablative Preconditioning Chemotherapy Followed by a Potential Consolidation Cycle is a PHASE1 clinical asset sponsored by Celyad Oncology SA in Acute Myeloid Leukemia, Myelodysplastic Syndrome. SEO and diligence focus: CYAD-02, ENDOXAN, Fludara, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.